Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 13,391 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Results available

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

NCT00199849
Conditions
Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Sarcoma
Interventions
NY-ESO-1 Plasmid DNA Cancer Vaccine
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Conditions
Renal Tumor, Renal Cell Carcinoma, Renal Tumor, Benign
Interventions
2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Conditions
Acute Kidney Injury, Abdominal Compartment Syndrome, Intraabdominal Hypertension, Cardiovascular Surgery
Interventions
Accuryn Monitoring System
Device
Lead sponsor
Potrero Medical
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Healthy, Renal Insufficiency
Interventions
Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
5
States / cities
Anaheim, California • Edgewater, Florida • Miami, Florida + 2 more
Conditions
Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions
Vandetanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Frequency, Urge Incontinence, Neurogenic Bladder
Interventions
Lidocaine 2% without vessel constrictor
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Chronic Kidney Disease, End Stage Renal Disease, Anemia
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
4
States / cities
Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463

NCT01812889
Conditions
Vaginal Infection
Interventions
TOL-463 Vaginal ovule, TOL-463 Vaginal gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Kidney Cancer
Interventions
ipilimumab
Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Efficacy and Safety of Votiva for Vaginal Rejuvenation

NCT03520426
Conditions
Vaginal Atrophy, Vaginal Relaxation, Stress Urinary Incontinence
Interventions
Votiva RF
Device
Lead sponsor
Walden, Jennifer L., M.D.,P.L.L.C.
Individual
Eligibility
25 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
New York, New York • Austin, Texas
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Randomized Trial of Pessary in Singleton Pregnancies With a Short Cervix

NCT02901626
Conditions
Short Cervix, Preterm Delivery
Interventions
Arabin Cervical Pessary
Device
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
544 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Chicago, Illinois • New York, New York + 9 more
Conditions
Vulvar Cancer
Interventions
Sentinel lymph node mapping
Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
72
States / cities
Little Rock, Arkansas • Long Beach, California • San Francisco, California + 53 more
Conditions
Polycystic Kidney Disease
Interventions
Niacinamide
Dietary Supplement
Lead sponsor
Alan Yu, MB, BChir
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Renal Cell Carcinoma
Interventions
AGS-003
Drug
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Chronic Kidney Diseases, Patient Requiring Heparin Free Dialysis Treatments
Interventions
Dialyzer with Endexo
Device
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
22 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
New Bern, North Carolina
Conditions
Atrophic Vaginitis
Interventions
Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more
Conditions
Ovarian Cancer, Fibroids, Uterine Cancer
Interventions
Bupivacaine, Liposomal bupivacaine
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orange, California
Conditions
Kidney Failure, Kidney Diseases
Interventions
Testim, 1% testosterone gel
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Palo Alto, California • San Jose, California
Conditions
Very Low Birth Weight Infant, Premature Infants, Anemia of Prematurity, Iron Deficiency, Anaemia in Children, Extremely Low Birth Weight
Interventions
6 mg/kg of oral iron as ferrous sulfate administered every other day., 6 mg/kg of oral iron as ferrous sulfate administered every day.
Dietary Supplement
Lead sponsor
CHRISTUS Health
Other
Eligibility
26 Weeks to 32 Weeks
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
End-Stage Kidney Disease, End-Stage Renal Disease
Interventions
Metoprolol Succinate, Carvedilol
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Long Beach, California • Aurora, Colorado • West Haven, Connecticut + 15 more
Withdrawn Not applicable Interventional Accepts healthy volunteers

E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy

NCT01986764
Conditions
Planned RRSO
Interventions
Lisdexamfetamine, Estradiol, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 48 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Recurrent Endometrial Carcinoma
Interventions
bevacizumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Adavosertib, Olaparib, Ceralasertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, ifosfamide, paclitaxel, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York